ATRX has occupied a special place in chromatin biology for more than two decades. Mutations in the ATRX gene cause alpha-thalassemia/mental retardation X-linked syndrome, a condition marked by severe intellectual disability, anemia, and characteristic changes in DNA methylation patterns. The protein belongs to the SWI/SNF family of ATP-dependent chromatin remodelers and carries a conserved ADD domain that reads chemical tags on histone H3, allowing ATRX to home in on specific regions of the genome. Early work established that ATRX binds highly repetitive, difficult-to-copy DNA sequences—tandem repeats, ribosomal DNA, pericentromeric heterochromatin, and telomeres—suggesting that its cellular job is to smooth out the rough patches of the genome. But precisely how ATRX accomplishes this, and which partner molecules divide the labor with it, has remained stubbornly unresolved. The new study tackles that question head-on by separating ATRX’s activities into discrete, mechanistically distinguishable functions and then testing how each one interfaces with the 9-1-1 and CST complexes.

The 9-1-1 complex, a heterotrimeric ring structurally related to the sliding clamps that tether DNA polymerases, is loaded onto recessed DNA junctions during replication stress. It functions as a platform for recruiting factors that restart stalled forks, enforce cell-cycle checkpoints, and fill in gaps left behind when the replication fork runs into trouble. The CST complex—composed of CTC1, STN1, and TEN1—was originally characterized as a helper for telomere maintenance, facilitating the synthesis of telomeric repeats by polymerase alpha-primase and protecting chromosome ends from inappropriate DNA damage responses. In recent years, however, CST has emerged as a genome-wide player: it fills in so-called C-strands at telomeres, assists with the completion of lagging-strand synthesis at difficult sites throughout the genome, and restarts replication after forks collapse. Because ATRX-deficient cells show hallmark signs of replication failure at telomeres and other repetitive regions, the possibility that ATRX and these two complexes operate in a common pathway was an obvious but untested hypothesis.

Using a combination of genetic epistasis experiments, live-cell imaging, and biochemical assays, the research team systematically perturbed ATRX, components of the 9-1-1 complex, and members of CST, then examined how these perturbations affected the cells’ ability to complete DNA synthesis at fragile genomic sites. The results reveal a layered defense architecture. One ATRX function—its capacity to remodel nucleosomes at problematic loci—acts upstream, preventing replication forks from stalling in the first place. A second, ATPase-independent function operates after fork trouble begins, cooperating with 9-1-1 to promote the resumption of DNA synthesis and the suppression of DNA damage signaling in regions that remain difficult to traverse. When either ATRX or the 9-1-1 clamp is disabled, cells accumulate under-replicated DNA and chromosome abnormalities that are characteristic of replication catastrophe, and the two defects are not additive—a genetic signature indicating that ATRX and 9-1-1 function in the same pathway rather than in parallel ones.

The telomere story is particularly striking. Telomeres terminate in single-stranded overhangs that must be filled in to form complete double-stranded DNA; failure to do so triggers chromosome-end fusions and catastrophic genome rearrangements. CST is the canonical executor of this fill-in reaction, recruiting and stimulating polymerase alpha-primase at chromosome ends. The new work shows that ATRX does not duplicate this function but rather supports it: in cells lacking ATRX, CST fails to complete its job efficiently at telomeres, leaving persistent single-stranded tails and exposing chromosome ends to aberrant repair. Restoring ATRX, or specifically rescuing its chromatin-remodeling activity at telomeric repeats, restores proper CST-dependent fill-in and eliminates the telomere dysfunction markers that otherwise accumulate. The authors present evidence that ATRX’s remodeling of the repetitive nucleosome arrays at telomeres creates a chromatin environment in which CST and the polymerase machinery can access their substrate—essentially clearing the molecular clutter that would otherwise block the repair crew.

This division of labor has significant implications for how scientists understand the genome-wide consequences of ATRX loss in human disease. ATRX syndrome patients carry mutations scattered across the protein, and previous studies had struggled to connect the dots between ATRX’s in vitro biochemical activities and the specific cellular phenotypes seen in patients. By demonstrating that distinct ATRX functions—nucleosome remodeling, checkpoint cooperation through 9-1-1, and CST-dependent telomere maintenance—can be genetically separated and mechanistically ordered, the study provides a framework for interpreting patient mutations. It suggests that different clinical presentations might correspond to different degrees of impairment in these parallel arms of ATRX function, opening the door to genotype-specific predictions about disease severity and, potentially, to therapeutic strategies that compensate for one defective arm by strengthening another.

The research also reframes a long-standing puzzle in telomere biology. Certain inherited disorders—collectively known as telomere biology disorders, including Coats plus syndrome and dyskeratosis congenita—arise from mutations in CST components themselves. The finding that ATRX acts upstream of CST in telomere maintenance suggests a functional connection between ATRX syndrome and these CST-linked diseases, even though the clinical symptoms differ. Both classes of patients show signs of shortened or dysfunctional telomeres, defective DNA replication at chromosome ends, and heightened sensitivity to replication stress. The new study provides a mechanistic bridge: it is the coordinated action of ATRX, 9-1-1, and CST that ensures telomeres are replicated and completed properly, and disruption at any point in this triad produces overlapping—but not identical—forms of genome instability.

From a broader perspective, the work speaks to one of the central organizing principles of modern genome biology: that the cell’s response to replication stress is not a single pathway but a combinatorial network, in which dedicated factors specialize in different classes of difficult DNA and in different stages of the replication process. ATRX, 9-1-1, and CST represent three nodes of this network—chromatin remodeling, fork restart, and DNA synthesis completion, respectively—and the new data show that they are not merely co-present at problematic sites but actively interdependent. Removal of any one node increases the burden on the others and, when that burden exceeds a threshold, converts a recoverable stall into an unrecoverable fork collapse. This kind of systems-level understanding is increasingly viewed as essential for predicting how cells fail under stress and how such failures propagate into disease.

The implications extend to cancer biology as well. ATRX is mutated or silenced in a substantial fraction of tumors, particularly gliomas, pancreatic neuroendocrine tumors, and certain sarcomas. These tumors frequently rely on an alternative mechanism of telomere maintenance, called alternative lengthening of telomeres or ALT, which uses homologous recombination to extend chromosome ends without the enzyme telomerase. The loss of ATRX is one of the most reliable predictors of ALT activation in clinical pathology, and the new findings provide a plausible mechanistic explanation: without ATRX to safeguard telomere replication and support CST-dependent fill-in, surviving cells are pushed toward recombination-based strategies to keep their chromosome ends intact. Understanding the precise molecular handoffs between ATRX, 9-1-1, and CST may therefore reveal vulnerabilities in ALT-positive cancers that could be exploited therapeutically, for instance by targeting the recombinational pathways that ATRX-deficient tumors depend upon.

The study, published in Nature Structural & Molecular Biology, represents a substantial step forward in resolving the functional anatomy of ATRX and situating it within the larger machinery that guards the genome during DNA replication. It replaces a broad and somewhat vague notion—ATRX protects difficult DNA—with a concrete, mechanistic model: ATRX remodels chromatin to prevent replication problems, cooperates with 9-1-1 to recover from the problems that still arise, and enables CST to complete the final steps of DNA synthesis at telomeres and other lagging-strand regions. As genome instability remains a driving force in cancer, aging, and inherited disease, dissecting these molecular partnerships is not merely an academic exercise; it is a necessary step toward interventions that can either prevent or exploit the failures of genome maintenance. The ATRX–9-1-1–CST axis now stands as one of the clearest examples of how the cell choreographs its replication machinery across the most treacherous stretches of the human genome—and of what goes wrong when that choreography breaks down.

Central to this pioneering research is the gene CHD8, a critical chromatin remodeler that regulates the transcriptional landscape of numerous genes involved in neurodevelopment. CHD8 mutations rank among the most significant genetic risk factors for ASD, influencing synaptic signaling, RNA splicing, and mitochondrial function—pathways deeply intertwined with the molecular etiology of autism and related neurodevelopmental disorders. While prior animal models carrying a heterozygous CHD8 mutation exhibited only mild phenotypic anomalies, severely limiting the exploration of more profound disease mechanisms, attempts to create homozygous mutants proved fatal, as embryos failed to survive. Overcoming this obstacle, the collaborative team engineered a novel viable homozygous CHD8 mutant mouse on a hybrid genetic background, permitting survival and enabling comprehensive studies of mutation severity.

This advanced mouse model has enabled the unprecedented examination of the differential phenotypic consequences of mild versus severe CHD8 mutations across sex lines—an aspect critical to understanding the sex-biased profile of autism. Investigations revealed that males harboring a mild mutation display behavioral and neurological abnormalities consistent with autism symptomatology, confirming previous observations and reflecting the human male bias in ASD diagnosis. Females with identical mild mutations, in contrast, exhibit a remarkable resilience attributed to a biological “female shield,” a temporary buffer mechanism that compensates for the genetic disruption and protects against overt autistic phenotypes. This observation confirms a dynamic protective capacity inherent in females rather than a static gender difference.

However, this biological safeguard is not immutable. The study unveiled that when the CHD8 mutation is intensified to a homozygous state, effectively doubling the genetic insult, the protective female shield collapses. Under these severe mutation conditions, both male and female mice manifest profound autism-related traits, including altered social behaviors and cognitive impairments, mirroring severe forms of ASD observed clinically. This finding importantly recalibrates our understanding of the sex difference in autism susceptibility, indicating that it is contingent upon the magnitude of genetic perturbation rather than being an absolute feature.

Beyond behavioral assessments, these genetically manipulated mice displayed significant neuroanatomical and physiological abnormalities. Enlarged brain volumes, disrupted cerebral blood flow, and aberrant neuronal oscillations were prominent in homozygous mutants, heralding dysfunctions within neural circuits crucial for cognitive processes. Additionally, transcriptomic analyses exposed extensive gene expression alterations involving synaptic signaling pathways, RNA splicing regulators, and mitochondrial bioenergetics. These molecular disruptions offer a mechanistic blueprint for the observed behavioral phenotypes and provide insight into the biological underpinnings of ASD’s heterogeneity.

The implication that sex differences in autism phenotypes are quantitatively modulated by genetic mutation severity redefines the conceptual framework for autism research. Rather than assuming fixed, binary sex-based vulnerabilities, this paradigm emphasizes a fluid spectrum where biological sex and genetic disruptions intersect synergistically. This nuanced perspective also extends its relevance to other neurodevelopmental disorders associated with CHD8 mutations, including attention deficit hyperactivity disorder (ADHD), intellectual disabilities, and schizophrenia, which also demonstrate sex-biased prevalence and may be influenced by mutation load.

Professor LEE Eunee from Yonsei University highlights the broader significance of these findings, emphasizing that the female biological shield’s existence informs why diagnostic and phenotypic patterns in autism differ across individuals and populations. She underscores the necessity of integrating consideration of both biological sex and mutation severity into clinical diagnostics, therapeutic development, and personalized medicine approaches for neurodevelopmental disorders. This research paves the way for future targeted interventions aimed at bolstering protective mechanisms or mitigating mutation severity.

Furthermore, Director KIM Eunjoon of the IBS Center for Synaptic Brain Dysfunctions articulates the transformative impact of this study. By successfully developing the viable homozygous CHD8 mutant mouse model, his team has achieved a milestone in dissecting the brain circuit and genetic mechanisms that drive severe autism. The revelation that sex differences in ASD phenotypes vary dynamically with genetic dosage establishes a foundational knowledge base for the precision therapeutics era, reinforcing the importance of individualized treatments tailored not just to genetic makeup but also to biological sex.

This research exemplifies the power of innovative genetic engineering combined with integrative behavioral, physiological, and molecular analyses to unravel intricate biological phenomena underlying complex neurodevelopmental disorders. It offers a clarion call for the scientific and medical communities to reevaluate clinical frameworks and encourages the continuous pursuit of mechanistically driven therapeutics that correspond to patients’ unique genetic and biological profiles.

The study was published in the esteemed journal Molecular Psychiatry on May 9th, 2026, and is expected to stimulate extensive follow-up research probing the molecular signatures of the female biological shield, the pathways mediating mutation-induced neuronal dysfunction, and the translational potential of these findings to human clinical populations.

Subject of Research: Animals

Article Title: Homozygous CHD8 mutation intensifies ASD phenotypes and attenuates sex differences

News Publication Date: 9-May-2026

Web References: 10.1038/s41380-026-03646-9

Image Credits: Institute for Basic Science

Keywords: Autism, Developmental disabilities, Mutation, Molecular genetics, Genetics, Developmental neuroscience, Brain development, Cognitive development, Intellectual disabilities, Learning disabilities, Attention deficit hyperactivity disorder, Mouse models, Animal models, Biological models, Computational biology

Autism spectrum disorder, a complex neurodevelopmental condition, has long been linked to rare genetic mutations that carry major risk implications. Yet, the vast majority of these genetic discoveries have emerged from studies primarily involving individuals of European descent, creating a significant research gap regarding autism’s genetic basis in other populations. This skew has saddled non-European individuals with less informative genetic test results, leaving many families without clear answers. The recent study addresses this disparity by bringing to light the shared genetic underpinnings of autism among Latin American populations, which are genetically diverse due to a history of Indigenous American, European, and African ancestries.

The investigation analyzed whole exome and whole genome sequencing data from over 15,000 Latin American individuals, which notably included approximately 4,700 diagnosed with autism. This cohort represents one of the largest and most varied ancestries ever assessed in autism genetics research. By examining more than 18,000 genes, the researchers focused on the enrichment of rare, deleterious coding variants—mutations that disrupt the function of proteins and are thus highly relevant to both clinical diagnostics and understanding disease mechanisms.

Findings from the study accentuate that rare damaging mutations in genes that remain evolutionarily conserved are disproportionately present in individuals diagnosed with autism. These genes have resisted extensive evolutionary changes across species over millions of years, indicating their pivotal biological functions. The identification of 35 genes with significant associations to autism in the Latin American cohort mirrors many genes previously implicated in European-ancestry studies, suggesting a core set of autism risk genes that transcend ancestral boundaries.

These discoveries also extend support to several recently identified “emerging” autism risk genes, which had lacked robust validation until now. The convergence of genetic risk factors across ancestries strengthens the hypothesis that the biological mechanisms driving autism are largely universal rather than population-specific. This insight has profound implications for research equity, urging the expansion of genetic databases to incorporate underrepresented populations to achieve more accurate and inclusive genetic diagnoses.

An integral part of the study also scrutinized the gene conservation metrics commonly used in clinical genetics to prioritize genes for their potential role in neurodevelopmental disorders. Historically, these metrics have been generated from datasets predominantly comprising individuals of European origin, possibly biasing evolutionary conservation estimates. The researchers found that while these metrics might generally overestimate conservation due to limited ancestral diversity, their accuracy remains reliable for highly conserved genes most pertinent to disorders like autism.

The continual inclusion of diverse genetic data from broad populations promises to refine these conservation metrics further. Improving the precision with which less conserved genes are evaluated will ultimately enhance clinical genetic testing accuracy. This progress is essential for advancing personalized medicine approaches, ensuring that people from all backgrounds receive equitable and precise diagnostic evaluations and treatment options.

Dr. Joseph D. Buxbaum, the study’s senior author and Director of the Seaver Autism Center for Research and Treatment at Mount Sinai, emphasized, “Our results indicate that the core genetic architecture of autism is shared across ancestries.” This affirmation reinforces the universality of the biological foundations of autism and calls for a more diverse and inclusive framework in genetic research. A more representative genomic landscape in science will bridge current health disparities and propel precision medicine forward.

The study’s methodological rigor combined observational analyses of both exome and genome sequencing data—two complementary genomic approaches that catalogue protein-coding regions and the entire genomic sequence, respectively. This dual approach allowed the researchers to capture rare deleterious mutations that could be obscured in less comprehensive studies or in those focusing only on a single population. Furthermore, the robust sample size and population diversity facilitated enhanced statistical power to detect gene-disease associations with greater confidence.

In the broader context, this research aligns with increasing evidence from studies of complex disorders, where both common and rare genetic variants appear to show substantial consistency across global populations. Such consistency underscores the feasibility and importance of building universal genetic models that are not overly reliant on any one population’s genetic information. Broadening participation in genomic research is thus a crucial step toward equitable healthcare and better outcomes for autism and related neurodevelopmental conditions worldwide.

Mount Sinai’s role as a major academic health system shines through in the translational efforts behind this work, bridging the gap between genomic discovery and clinical application. Its emphasis on integrating cutting-edge genomic science with patient-centered care exemplifies the transformative potential of multidisciplinary research collaborations. Leveraging advanced bioinformatics, artificial intelligence, and diverse genetic datasets sets a new precedent for future studies in the field.

This study heralds a new chapter in autism research and genomics. Beyond its immediate scientific impact, it carries a powerful social message: that inclusivity in research not only promotes justice but also enhances the scientific robustness of findings that affect millions of lives. Continued efforts to include underrepresented populations in genetic research hold the promise of delivering more equitable diagnostics, therapies, and support for families across all ancestries affected by autism spectrum disorder.

Subject of Research: People
Article Title: Deleterious coding variation associated with autism is shared across ancestries
News Publication Date: 30-Mar-2026
Web References: https://www.mountsinai.org, https://www.nature.com/articles/s41591-026-04228-6
References: DOI: 10.1038/s41591-026-04228-6
Image Credits: Marina Natividad Avila, MSc
Keywords: Autism, Genomics, Genome sequencing, Genomic analysis, Exome sequencing

Autism Spectrum Disorder is a multifaceted neurodevelopmental disorder characterized by a range of challenges, including difficulties in communication, social interaction, and repetitive behaviors. Despite extensive research, the genetic etiology of ASD remains poorly understood, partly due to its heterogeneous nature. This means that the genetic factors contributing to the disorder can vary widely among individuals, complicating efforts to identify consistent genetic markers. However, the Iranian team’s recent work sheds light on novel genetic mutations that could have significant implications for our understanding of the disorder.

The researchers, led by Mirahmadi, employed whole-exome sequencing, which targets protein-coding regions of the genome known to harbor mutations linked to diseases. This method allows for a more focused analysis of genetic variations that may disrupt normal protein function. In conjunction with whole-genome sequencing, which examines the entirety of an individual’s genetic material, the study was able to provide a comprehensive picture of genetic influences on ASD.

Among the genes identified in the study are RIMS2, FOXG1, AUTS2, ZCCHC17, and SPTBN5. Each of these genes has established connections to neurological functions, underscoring their potential relevance in the manifestation of autism. For instance, mutations in FOXG1 are known to be associated with neurodevelopmental disorders, and alterations in AUTS2 have been implicated in various forms of intellectual disability and autism. This research highlights the importance of understanding how these genes interact and contribute to the spectrum of autistic traits.

One of the more intriguing aspects of this research is its focus on Iranian families, a demographic that has been less represented in genetic studies of ASD. The unique genetic landscape of this population may reveal novel insights that diverge from findings in more commonly studied cohorts. This is particularly relevant in genetic research, where population diversity can significantly influence the understanding of disease mechanisms. By investigating a distinct group, the researchers aim to broaden the scope of genetic knowledge surrounding ASD.

The novel mutations identified provide potential pathways for future research aimed at uncovering the molecular mechanisms of ASD. Understanding how these mutations affect brain development and function could illuminate new targets for therapeutic intervention. For families affected by autism, this research offers a glimmer of hope that genetic advancements may soon translate into improved diagnostic methods and potential treatments tailored to their specific genetic makeup.

Furthermore, the methodological approach taken by the researchers serves as a valuable template for future studies in the field. Utilizing both whole-exome and whole-genome sequencing maximizes the likelihood of discovering impactful genetic variants. Such comprehensive genetic profiling could also pave the way for precision medicine in ASD, wherein treatments are customized according to the individual’s unique genetic characteristics.

In addition to its implications for diagnosis and treatment, this study underscores the importance of collaboration in genetic research. By working with families affected by autism, the research team has positioned itself to gather critical data that reflects the lived experiences of individuals with ASD. This participatory approach not only enriches the research but also fosters a sense of community and support among families.

As researchers continue to unravel the genetic underpinnings of Autism Spectrum Disorder, it is clear that no single mutation will explain the vast array of symptoms and experiences associated with ASD. However, studies like this one highlight that, through rigorous examination of genetic variation, there remains a significant potential for advancing our understanding of the disorder. Each identified mutation can act as a piece of a complex puzzle, leading us closer to comprehensive models of autism that incorporate genetic, environmental, and developmental factors.

The implications of these findings extend beyond academic interest; they suggest a shift toward more nuanced approaches in the evaluation and management of ASD. Importantly, the work encourages ongoing research into the intersection of genetics and neurodevelopmental disorders, maintaining a focus on diversity in genetic studies. As we continue to confront the challenges posed by autism, it is studies such as this that may ultimately lead us toward effective solutions and improved outcomes for those affected by the disorder.

In conclusion, the identification of novel mutations in key genes associated with Autism Spectrum Disorder within Iranian families represents a significant advancement in the field of genetics. By leveraging sophisticated sequencing technologies and adopting an inclusive research approach, the team led by Mirahmadi has opened new avenues for exploration that may revolutionize our understanding of autism. With ongoing research and collaboration, the hope is to develop more effective strategies for diagnosis, intervention, and support for individuals and families navigating the complexities of ASD.

Subject of Research: Genetic Heterogeneity of Autism Spectrum Disorder

Article Title: Genetic Heterogeneity of Autism Spectrum Disorder: Identification of Five Novel Mutations (RIMS2, FOXG1, AUTS2, ZCCHC17, and SPTBN5) in Iranian Families via Whole-Exome and Whole-Genome Sequencing.

Article References:

Mirahmadi, M., Kahani, S.M., Sharifi-Zarchi, A. et al. Genetic Heterogeneity of Autism Spectrum Disorder: Identification of Five Novel Mutations (RIMS2, FOXG1, AUTS2, ZCCHC17, and SPTBN5) in Iranian Families via Whole-Exome and Whole-Genome Sequencing.
Biochem Genet (2025). https://doi.org/10.1007/s10528-025-11226-9

Image Credits: AI Generated

DOI: 10.1007/s10528-025-11226-9

Keywords: Autism Spectrum Disorder, Genetic Mutations, Whole-Exome Sequencing, Whole-Genome Sequencing, Neurodevelopmental Disorders

Professor Franke’s scientific trajectory took a defining turn during a laboratory practical where she isolated DNA from HeLa cells — a moment she recalls with fondness as her “love affair” with molecular genetics began. Shifting her focus from primatology and the study of great apes in the wild to the complex genetic architecture of human brain disorders, Franke embarked on a mission to decode the biological pathways that govern behavior. This pivot marked the start of what would become a distinguished career addressing some of psychiatry’s most elusive questions.

With a publication record exceeding 500 peer-reviewed articles, Professor Franke ranks among the global elite of highly cited scientists. Her research goes beyond mere gene mapping; it employs integrative approaches combining genomics, bioinformatics, and experimental biology, spanning model systems from Drosophila melanogaster to human induced pluripotent stem cells. This multidisciplinary strategy allows her to explore how subtle genetic differences manifest as behavioral phenotypes, offering critical insights into neurodevelopmental conditions’ etiology.

Franke’s prominent role in founding consortia such as the International Multicentre persistent ADHD